Previous 10 | Next 10 |
ATLANTA, April 13, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announces top-line r...
ATLANTA, March 31, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has appointed Steven T. Gill as Vice President, Thought Lea...
ATLANTA, March 25, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that nin...
Image source: The Motley Fool. Alimera Sciences Inc (NASDAQ: ALIM) Q4 2019 Earnings Call Feb 27, 2020 , 9:00 a.m. ET Operator Continue reading
Alimera Sciences, Inc. (ALIM) Q4 2019 Earnings Conference Call February 27, 2020 9:00 AM ET Company Participants Jules Abraham - CORE IR Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Andrew D'Silva ...
Alimera Sciences (NASDAQ: ALIM ): Q4 GAAP EPS of $0.08 beats by $0.53 . More news on: Alimera Sciences, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
Fourth Quarter Highlights: Consolidated Net Revenue of $17.3 Million; Up 15% Over Q4 2018 International Net Revenue Up 26% Compared to Q4 2018 Net Income of $498,000 vs. Net Loss of $1.2 million in Q4 2018 $2.6 million Positive Adjusted EBITDA Year End 2019 H...
ATLANTA, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that it has drawn down the remaining...
ATLANTA, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it will report fourth quarter and full year 2019 fina...
CHICAGO , Jan. 27, 2020 /PRNewswire/ -- Private investor, Ronald Chez , increases Alimera position. Media contact: Elias Matsakis , Holland & Knight LLP View original content: http://www.prnewswire.com/news-releases/alimera-sciences-inc-13da-filing-300992952.html SOUR...
News, Short Squeeze, Breakout and More Instantly...
Alimera Sciences Inc. Company Name:
ALIM Stock Symbol:
NASDAQ Market:
Alimera Sciences Inc. Website:
2024-07-07 16:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / July 3, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Perficient, Inc. (NASDAQ:PRFT)'s sal...
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Alimera Sciences, Inc. (NASDAQ:ALIM)'...